文献速递临床免疫临床生化

阿尔茨海默病血浆标志物化学发光免疫分析 panel 的分析验证与临床性能初步研究

Analytical validation and clinical performance of a chemiluminescence immunoassay panel for plasma biomarkers in Alzheimer's disease: a preliminary study.
PubMed 文献 · Clin Chim Acta · 2026-08-29

本研究在全自动化学发光免疫分析平台(Shine i2910)上开发并验证了同时定量六种核心血浆AD标志物(Aβ1-40、Aβ1-42、p-Tau181、p-Tau217、GFAP和NfL)的方法。对北京天坛医院87例确诊住院患者(AD、其他痴呆、MCI)血浆样本进行检测,分析性能符合CLSI指南要求,AD患者p-Tau181、p-Tau217显著升高且Aβ1-42/Aβ1-40显著降低,所有标志物ROC曲线AUC>0.7。

要点

  • 全自动CLIA panel可同时定量六种血浆AD标志物,分析性能良好。
  • AD患者血浆p-Tau181、p-Tau217显著高于OD和MCI,Aβ1-42/Aβ1-40显著降低。
  • 所有标志物AUC>0.7,支持AD辅助鉴别诊断,但需多中心验证。

核心结论

  • 全自动CLIA平台可快速、高性能定量六种核心血浆AD标志物,分析性能满意,提供成本效益好、微创的AD辅助筛查替代方案。

研究设计与样本

  • 单中心探索性研究,采用全自动CLIA平台(Shine i2910,Vazyme,中国)检测87例北京天坛医院确诊住院患者血浆样本,分为AD、其他痴呆(OD)和轻度认知障碍(MCI)三组。
  • 分析性能验证依据CLSI指南(EP15-A3、EP09-A3、EP06-A2、EP17-A2)进行,包括精密度、准确度、线性和检测限。

主要发现

  • 所有六种标志物批内CV<3%,批间CV<5%,相对偏差<±10%,线性相关系数R²>0.99,检测灵敏度达亚皮克级。
  • AD患者血浆p-Tau181和p-Tau217浓度显著高于OD和MCI患者,Aβ1-42/Aβ1-40显著降低(p<0.05)。
  • GFAP和NfL在AD和OD患者中均显著高于MCI患者(p<0.05),AD与OD之间无显著差异。
  • ROC曲线分析显示所有标志物AUC>0.7,支持AD辅助鉴别诊断。

关键数值与推荐

  • 批内CV<3%,批间CV<5%,相对偏差<±10%,线性R²>0.99,检测灵敏度达亚皮克级。
  • AD与OD/MCI比较p-Tau181、p-Tau217升高及Aβ1-42/Aβ1-40降低的p<0.05。
  • GFAP和NfL在AD和OD中高于MCI的p<0.05。
  • 所有标志物ROC曲线AUC>0.7。

临床怎么用

  • 该CLIA panel可用于临床研究条件下AD的辅助筛查和鉴别诊断,尤其p-Tau181、p-Tau217及Aβ1-42/Aβ1-40组合有助于区分AD与OD/MCI。
  • GFAP和NfL可辅助区分MCI与痴呆(AD或OD),但不能区分AD与OD。

局限性

  • 单中心探索性研究,无匹配健康对照,仅提供分析验证和初步临床鉴别证据。
  • 需大规模多中心队列验证其真实世界大规模筛查价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alzheimer's disease (AD) poses a growing global health challenge, highlighting the urgent need for reliable and minimally invasive diagnostic tools. This study aimed to develop and comprehensively validate an automated chemiluminescence immunoassay (CLIA) for the simultaneous quantification of six core plasma AD biomarkers: Aβ1-40, Aβ1-42, p-Tau181, p-Tau217, GFAP and NfL. METHODS: A fully automated CLIA platform (Shine i2910, Vazyme, China) was utilized for biomarker detection. A total of 87 plasma samples from hospitalized patients with confirmed diagnosis at Beijing Tiantan Hospital were stratified into three cohorts: AD, Other Dementia (OD), and Mild Cognitive Impairment (MCI). The analytical performance of the assay, including precision, accuracy, linearity, and detection limits, was validated in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines (EP15-A3, EP09-A3, EP06-A2, EP17-A2). RESULTS: This CLIA panel achieved robust analytical metrics, with within-run coefficient of variation (CV) < 3%, between-run CV < 5%, relative bias < ±10%, and linear correlation coefficient (R2) > 0.99 for all six biomarkers, along with sub-picogram level detection sensitivity. Clinical sample analysis revealed that AD patients had significantly higher plasma concentrations of p-Tau181 and p-Tau217, along with a significantly reduced Aβ1-42/Aβ1-40, compared with OD and MCI patients (p < 0.05). GFAP and NfL concentrations were significantly elevated in both AD and OD patients relative to the MCI patients (p < 0.05), with no significant difference between AD and OD patients. Receiver operating characteristic (ROC) curve analysis demonstrated an area under the curve (AUC) > 0.7 for all biomarkers, supporting auxiliary differential diagnosis of AD and demonstrating the assay's clinical discriminatory ability. CONCLUSION: The developed fully automated CLIA platform enables rapid, high-performance quantification of six core plasma AD biomarkers with satisfactory analytical performance. As a single-center exploratory study without matched healthy controls, this study only provides analytical validation and preliminary clinical discriminatory evidence. It offers a cost-effective, minimally invasive alternative for auxiliary AD screening under clinical research conditions, while large multi-center cohorts are required to verify its real-world large-scale screening value.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Chen X, Jiang W, Wang L, et al. Analytical validation and clinical performance of a chemiluminescence immunoassay panel for plasma biomarkers in Alzheimer's disease: a preliminary study. Clin Chim Acta. 2026. PMID: 42668129. doi:10.1016/j.cca.2026.121300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。